Loading...
Standard of Care and Controversies in the Adjuvant Endocrine Treatment of Hormone-Responsive Early Breast Cancer
Hormone-responsive early breast cancer is a highly curable disease. In premenopausal women, tamoxifen (TAM) is still the standard treatment. Nowadays, up to 10 years of TAM can be safely administered, especially in women who remain premenopausal. Patients who are considered to be perimenopausal shou...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
S. Karger GmbH
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4209275/ https://ncbi.nlm.nih.gov/pubmed/25404889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000365561 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|